PTSM: Pharmaceutical Technology Sourcing and Management
CSafe and AES will support controlled-temperature shipping through the Basel, Switzerland airport from their new service center.
CSafe Global, which manufactures passive and active containers for controlled-temperature shipping, including its RKN refrigeration unit for aircraft, opened a new, full-service center serving the Basel, Switzerland area. The recently opened service center is also a new location for Airplane Equipment & Services (AES), which also supports CSafe in Frankfurt and Cologne.
“The use of the CSafe RKN continues to grow out of Switzerland, and we are very excited about adding to our relationship with Airplane Equipment Services," said Brian Kohr, president and CEO of CSafe Global, in a press release. "The opening of the new service center as of June 1 meets our strategic timeline in expanding our CSafe RKN service and maintenance network to support growing customer demand. Where we were able to provide some services and stocking of containers in Basel in the past, the new location is capable of performing repair work.”
“It is our mission to see to it that the CSafe RKN’s are appropriately and professionally handled, inspected, stored, and prepared for their next use,” said Willy Reinhardt, managing director of AES, in the press release.
In March 2015, CSafe opened a service center at the Seattle-Tacoma, Washington airport, in conjunction with Total Air Group, to support temperature-sensitive biopharmaceutical shipments on the US west coast.
Source: CSafe Global
WMFTS’ BioPure to Showcase Single-Use Bioclamp with Refined Manufacturing at INTERPHEX 2025
April 1st 2025With advanced manufacturing, BioPure’s BioClamp connector is manufactured to be 13% lighter than the previous model, resulting in a 26% reduction in carbon dioxide emissions across the full lifecycle of the product.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.